Treatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy

Cancer Biology and Therapy

Volumn 13, Issue 8, 2012, Pages 600-605

  Ramos Suzarte, Mayra ^a   Lorenzo Luaces, Patricia ^a   Lazo, Nery Gonzalez ^b   Perez, Mayte Lima ^c   Soriano, Jorge Luis ^c   Gonzalez, Carmen Elena Viada ^a   Hernadez, Ivis Mendoza ^d   Albuerne, Yisel Ávila ^d   Moreno, Beatriz Paredes ^d   Alvarez, Eduardo Santiesteban ^e   Callejo, Idael Pineda ^a   Alert, Jose ^b   Martell, Juan Antonio ^d   Gonzalez, Yanela Santiesteban ^a   Gonzalez, Yulainis Santiesteban ^a   De La Vega, Horacio Astudillo ^f   Ruiz Garcia, Erika Betzabe ^g   Crombet Ramos, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^c HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^d National Coordinating Centre for Clinical Trials   (Cuba)

^e Jose Ramon Lopez Tabranes Oncology Hospital   (Cuba)

^f HOSPITAL DE ONCOLOGÍA   (Mexico)

^g National Mexican Institute of Cancer (IN CAM)   (Mexico)

Author keywords

Chemorariotherapy; Esophageal cancer; Humanized monoclonal; Nimotuzumab

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; NIMOTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS TUMOR; FEMALE; FEVER; GENE MUTATION; GENE OVEREXPRESSION; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PROTEIN EXPRESSION; RADIATION DERMATITIS; RETROSTERNAL PAIN; TREATMENT DURATION; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; GENETICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 85047688466     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19849     Document Type: Article

References (42)

1. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010; 31:100-10; PMID:19934210; http://dx.doi.org/10.1093/carcin/bgp263.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287-9; PMID:1995976; http://dx.doi.org/10.1001/jama.1991.03460100089030.
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049-53; PMID:9827707; http://dx.doi.org/10.1002/(SICI)1097-0142(19981115)83: 10〈2049::AIDCNCR1〉3.0.CO;2-2.
4. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of prospective randomized trial (Radiation Therapy Oncology Group 85-01). JAMA 1999; 281:1623-7; PMID:10235156; http://dx.doi.org/10.1001/jama. 281.17.1623.
5. Nemoto K. Current Status of Radiation Therapy-Evidence-based Medicine (EBM) of addition Therapy-Current Management of Patients with Esophageal Cancer. Nippon Igaku Hoshasen Gakkai Zasshi 2001; 62:132-7.
6. Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005; 31:453-60; PMID:15922879; http://dx.doi.org/10.1016/j.ejso.2005.02.026.
7. Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996; 14:156-63; PMID:8558191.
8. Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; 1799; PMID:16235286.
9. Ku GY, Ilson DH. Esophageal cancer: adjuvant therapy. Cancer J 2007; 13:162-7; PMID:17620765; http://dx.doi.org/10.1097/PPO.0b013e318074dbe7.
10. Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, et al. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009; 24:886-95; PMID:19655439; http://dx.doi.org/10.1111/j.1440-746.2008.05732.x.
11. Czito BG, Willett CG. In Pursuit of Progress: Multimodality Strategies Will Form the Cornerstone of Cure for Esophageal Cancer. Gastrointest Cancer Res 2009; 3:74-6.
12. Lagarde SM, Vrouenraets BC, Stassen LP, van Lanschot JJ. Evidence-based surgical treatment of esophageal cancer: overview of high-quality studies. Ann Thorac Surg 2010; 89:1319-26; PMID:20338377; http://dx.doi.org/10.1016/j. athoracsur.2009.09.062.
13. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142:3714-25; PMID:2785562.
14. Schlag PM; Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992; 127:1446-50; PMID:1365692; http://dx.doi.org/10.1001/archsurg.1992. 01420120080015.
15. Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Williston Park) 1994; 8:37-42; PMID:7527642.
16. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 2000; 6:4663-73; PMID:11156218.
17. Ekman S, Bergqvist M, Tell R, Bergström S, Lennartsson J. Hsp90 as a therapeutic target in patients with oesophageal carcinoma. Expert Opin Ther Targets 2010; 14:317-28; PMID:20148718; http://dx.doi.org/10.1517/ 14728221003621278.
18. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 2002; 22:1737-54; PMID:12168863.
19. Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006; 6:1205-14; PMID:16842157; http://dx.doi.org/10.2174/ 156802606777812068.
20. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300:1887-96; PMID:18940975; http://dx.doi.org/10.1001/jama.300.16.1887.
21. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new para-digm in immunotherapy? MAbs 2009; 1:12-25; PMID:20046569; http://dx.doi.org/10.4161/mabs.1.1.7347.
22. Dragovich T, Campen C. Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. J Oncol 2009; 804108. Available in: http://www.ncbi.nlm.nih.gov/pubmed/19636422.
23. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-81; PMID:9154469; http://dx.doi.org/10.1016/S1380-2933(97)00065-1.
24. Crombet TC, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-54; PMID:15117987; http://dx.doi.org/10.1200/JCO.2004.03.089.
25. Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006; 5:375-9; PMID:16575203; http://dx.doi.org/10.4161/cbt.5. 4.2522.
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.; Toxicity and response criteria of the eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55; PMID:7165009; http://dx.doi.org/10.1097/00000421- 198212000-00014.
27. Karnofsky D, Abelmann W, Craver L, Burchenal J. The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1948; 1:634-56; http://dx.doi.org/10.1002/1097-0142(194811)1:4〈634::AIDCNCR2820010410〉 3.0.CO;2-L.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/92.3. 205.
29. European organization for research and treatment of cancer.EORTC QLQ-C30. Available from: http://groups.eortc.be/qol/downloads/modules/specimen-20qlq- c30.pdf
30. European organisation for research and treatment of cáncer. EORTC QLQ-OES18. Available from: http://groups.eortc.be/qol/downloads/modules/ specimen-20qlq-oes18.pdf
31. Essack M, Radovanovic A, Schaefer U, Schmeier S, Seshadri SV, Christoffels A, et al. DDEC: Dragon data-base of genes implicated in esophageal cancer. BMC Cancer 2009; 9:219; PMID:19580656; http://dx.doi.org/10.1186/1471- 2407-9-219.
32. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27:1130-6; PMID:19124802; http://dx.doi.org/10.1200/JCO.2008.19.8168.
33. Torres OJ, Peña L, Martínez LB, Padilla D, Rodríguez K. Impact of the GCP System in the Clinical Trials. Control Clin Trials 2003; 24:126.
34. Ilson DH. New developments in the treatment of esophageal cancer. Clin Adv Hematol Oncol 2004; 2:97-104; PMID:16163169.
35. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006; 12:6064-72; PMID:17062682; http://dx.doi.org/ 10.1158/1078-0432.CCR-06-0910.
36. Jiménez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F, et al. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer 2008; 8:78; PMID:18366723; http://dx.doi.org/10.1186/1471-2407-8-78.
37. Liu W, Zhang X, Sun W. Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol 2008; 9:375-87; PMID:19396633; http://dx.doi.org/10.1007/s11864-009-0097-1.
38. Wang W, Xue L, Liu H, Wang P, Xu P, Cai Y. Aberrant changes of Wnt2/beta-catenin signaling pathway induced by sodium nitroprusside in human esophageal squamous cell carcinoma cell lines. Cancer Invest 2010; 28:230-41; PMID:19857041; http://dx.doi.org/10.3109/07357900903095698.
39. Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep 2010; 23:1167-72; PMID:20204306.
40. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res 2009; 3:153-61; PMID:19742141.
41. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20:1667-73; PMID:19549707; http://dx.doi.org/10.1093/annonc/mdp069.
42. National Comprehensive Cancer Network. NCCN Guidelines and Clinical Resources. Access 2011; http://www.nccn.org/professionals/physician-gls/f- guidelines.asp